



Imaxio receives scientific advice from the European Medicines Agency (EMA) for its influenza vaccine candidate IMX836

Imaxio plans to make IMX836 reach the clinic by early 2018

Lyon, France – March 16, 2017 – Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.

This first scientific advice reinforces Imaxio's plan to start, by early 2018, a phase I clinical trial involving IMX836.

Imaxio's influenza vaccine candidate IMX836 is being developed as an add-on to seasonal vaccines, in order to improve the effectiveness of prevention through vaccination, especially in elderly people. It is based on IMX313P, a pro-immunogenic antigen re-engineering technology owned by Imaxio.

"The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention," said Alexandre Le Vert, Chief Executive Officer of Imaxio. "With this scientific advice from the EMA, we confirm the IMX836 roadmap to enter the clinic by early 2018."

The World Health Organization (WHO) estimates that seasonal influenza epidemics result in 3 to 5 million serious cases every year. With 250,000 to 500,000 annual deaths recorded worldwide, there is a strong medical need to improve current influenza vaccines, particularly in the elderly and for numerous strains of influenza, both seasonal and pandemic.

About Imaxio

Imaxio is a small biotechnology company focused on immunology, with products ranging from commercial stage to clinical and preclinical R&D stages.

Imaxio commercializes in France a human vaccine indicated for the prevention of an infectious occupational disease, called Spirolept®.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases (malaria, influenza, etc.) and an immunotherapy in oncology.

It is based on the IMX313(P) technology, an antigen re-engineering platform developed by Imaxio to improve the efficacy of vaccines, which is protected by a strong portfolio of 4 patent families.



Imaxio partners with national and international renowned research structures, including the Jenner Institute at Oxford University (UK), the German Cancer Research Centre (DKFZ), Inserm (France), CNRS (France) and the Léon Bérard Cancer Centre (Lyon, France).

Based in Lyon (France), more than half of the twenty Imaxio employees is dedicated to R&D activities. In 2016, its turnover reached EUR 2.2 million.

For further information: www.imaxio.com